2Kremer LC,Van der Pal HJ,Offringa M,et al.Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children:a systematic review[J] Ann Oncol,2002,13(6):819-829.
3Jensen BV,Skovsgaard T,Nielsen SL.Functional monitoring of anthracycline cardiotoxicity:a prospective,blinded,long-term observational study of outcome in 120 patients[J].Ann Oncol,2002,13(5):699-709.
4Messinger Y,Uckun FM.A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia[J] Leuk Lymphoma,1999,34(5-6):415-432.
5Rammeloo LA,Postma A,Sobotka-Plojhar MA,et al.Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia:no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group[J].Med Pediatr Oncol,2000,35(1):13-19.
7Krischer JP,Epstein S,Cuthbertson DD,et al.Clinical cardiotoxicity following anthracycline treatment for childhood cancer:the Pediatric Oncology Group experience[J].J Clin Oncol,1997,15(4):1 544-1 552.
8de Beer EL,Bottone AE,Van Der Velden J,et al.Doxorubicin impairs crossbridge turnover kinetics in skinned cardiac trabecube after acute and chronic treatment[J] Mol Pharmacol,2000,57(6):1 152-1 157.
9Forrest GL,Gonzalez B,Tseng W,et al.Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice[J].Cancer Res,2000,60(18):5 158-5 164.
10Cusack BJ,Musser B,Gambliel H,et al.Effect of dexrazoxane on doxorubicin pharmacokinetics in young and old rats[J] Cancer Chemother Pharmacol,2003,51(2):139-146.
